Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-13,244
Closed -$879K 473
2025
Q4
$879K Buy
+13,244
New +$856K 0.11% 222
2024
Q4
Sell
-90,577
Closed -$6.07M 440
2024
Q3
$6.07M Buy
+90,577
New +$7.44M 0.71% 31
2023
Q3
Sell
-17,571
Closed -$2.26M 495
2023
Q2
$2.26M Buy
+17,571
New +$2.13M 0.32% 91
2021
Q4
Sell
-14,260
Closed -$1.95M 356
2021
Q3
$1.95M Buy
+14,260
New +$1.8M 0.49% 58
2021
Q2
Sell
-1,396
Closed -$125K 937
2021
Q1
$125K Buy
+1,396
New +$131K 0.04% 372
2020
Q3
Sell
-24,492
Closed -$2.48M 727
2020
Q2
$2.48M Sell
24,492
-30,904
-56% -$2.76M 0.85% 12
2020
Q1
$3.73M Buy
55,396
+6,728
+14% +$419K 0.81% 16
2019
Q4
$2.66M Buy
+48,668
New +$2.31M 0.27% 84

Other funds holding DXCM

FORA Capital's DXCM Position: Q1 2026 in Review

FORA Capital sold out of DexCom (DXCM) in Q1 2026, closing a stake of 13,244 shares — an estimated $879K sold.

FORA Capital first reported a position in DXCM in Q4 2019 and held it in 8 quarters. The position peaked at $6.07M in Q3 2024. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • FORA Capital reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
  • FORA Capital sold 13,244 DexCom shares in Q1 2026, an estimated $879K.
  • FORA Capital first reported a position in DexCom in Q4 2019 and held it in 8 quarters.
  • FORA Capital's DexCom position peaked at $6.07M in Q3 2024.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.